A client who has been diagnosed with exercise-induced asthma is prescribed zafirlukast (Accolate). Which of the following adverse effects would the nurse inform the client regarding zafirlukast (Accolate)?
Liver injury
bradycardia
renal failure
Bronchoconstriction
The Correct Answer is A
A) Liver injury: Zafirlukast (Accolate) has been associated with the risk of liver injury. It is important for clients to be informed about this potential adverse effect, as it may require monitoring of liver function tests during treatment. Symptoms of liver injury, such as jaundice, dark urine, or severe fatigue, should prompt clients to seek medical attention.
B) Bradycardia: Bradycardia is not a commonly associated adverse effect of zafirlukast. This medication primarily works as a leukotriene receptor antagonist and does not typically affect heart rate significantly. Clients should be aware of other more relevant side effects rather than bradycardia.
C) Renal failure: Renal failure is not a known adverse effect of zafirlukast. While kidney function should always be monitored in patients taking various medications, zafirlukast specifically does not have a direct association with renal failure.
D) Bronchoconstriction: While bronchoconstriction is a concern in asthma management, zafirlukast is designed to prevent bronchoconstriction by blocking leukotriene receptors. Therefore, it is not an adverse effect of the medication. In fact, its purpose is to help reduce the incidence of bronchoconstriction and improve asthma control.
Free Nursing Test Bank
- Free Pharmacology Quiz 1
- Free Medical-Surgical Quiz 2
- Free Fundamentals Quiz 3
- Free Maternal-Newborn Quiz 4
- Free Anatomy and Physiology Quiz 5
- Free Obstetrics and Pediatrics Quiz 6
- Free Fluid and Electrolytes Quiz 7
- Free Community Health Quiz 8
- Free Promoting Health across the Lifespan Quiz 9
- Free Multidimensional Care Quiz 10
View Related questions
Correct Answer is A
Explanation
A. "Make sure to use this each time I feel an asthma attack coming on": This statement indicates a need for further education. LABAs are not intended for immediate relief of acute asthma symptoms or attacks; they are designed for long-term control and prevention of symptoms. Clients should use a short-acting beta agonist (SABA) for quick relief during an asthma attack, not a LABA.
B. "I know that these drugs can sometimes make my heart beat faster": This statement reflects an understanding of a potential side effect of LABAs. Increased heart rate is a known side effect, and it is important for clients to be aware of this possibility.
C. "I've heard that this drug sometimes gets less effective over time": This statement is accurate. Tolerance can develop with LABA use, and clients should be informed about this possibility to monitor their symptoms and report any changes to their healthcare provider.
D. "I've heard that this drug is particularly good at preventing asthma attacks during exercise": This statement is correct. LABAs can be beneficial for preventing exercise-induced bronchospasm when used as part of a regular asthma management plan, and clients should understand this use.
Correct Answer is A
Explanation
A. This medication is for long-term treatment for asthma: This statement indicates an accurate understanding of montelukast. It is a leukotriene receptor antagonist used for long-term control and management of asthma symptoms and to prevent exercise-induced bronchoconstriction.
B. This medication has a tendency to produce anaphylaxis: This statement is incorrect. While allergic reactions can occur with montelukast, it is not commonly associated with anaphylaxis. Clients should be aware of potential side effects, but anaphylaxis is not a common risk.
C. I can repeat this medication twice prior to seeking medical attention: This statement is misleading. Montelukast is taken once daily for asthma management, and it is not meant to be repeated or used as a rescue medication in acute situations. Clients should seek medical attention for worsening symptoms instead of relying on repeating doses.
D. Bloodwork is required regularly to monitor the therapeutic levels of this medication: This statement is incorrect. Montelukast does not require routine blood monitoring for therapeutic levels, unlike some other medications used for asthma management. It is generally well-tolerated without the need for regular blood tests.